Topiramate for the prophylaxis of episodic migraine in adults (Q24201849)

9 December 2023

Wim M Mulleners

series ordinal

2

author given names

Wim M

author last names

Mulleners

1 reference

9 December 2023

Edward P Chronicle

series ordinal

3

author given names

Edward P

author last names

Chronicle

1 reference

9 December 2023

Douglas C McCrory

series ordinal

4

author given names

Douglas C

author last names

McCrory

1 reference

Cochrane Database of Systematic Reviews

9 December 2023

language of work or name

1 reference

24 June 2013

0 references

published in

0 references

cites work

A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate for migraine prevention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate in migraine prevention: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Efficacy of topiramate and valproate in chronic migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Antiepileptic drugs: how they work in headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Clinical assessment of topiramate therapy in patients with migrainous vertigo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Migraines with and without aura and their response to preventive therapy with topiramate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate in the Treatment of Chronic Migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Economic and social impact of migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non-epileptic central nervous system disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD010610

21 January 2018

12 December 2020

New drugs in migraine treatment and prophylaxis: telcagepant and topiramate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

The cost of headache disorders in Europe: the Eurolight project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Self-medication of regular headache: a community pharmacy-based survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

New appendix criteria open for a broader concept of chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Drugs for preventing migraine headaches in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Anticonvulsant drugs for acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Anticonvulsant drugs for migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Anticonvulsants in migraine prophylaxis: a Cochrane review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010610

Topiramate for migraine prophylaxis among Chinese population

21 January 2018

1 reference

12 December 2020

A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis

1 reference

12 December 2020

Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials.

1 reference

12 December 2020

Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).

1 reference

12 December 2020

Assessing the ability of topiramate to improve the daily activities of patients with migraine

1 reference

12 December 2020

Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study

1 reference

12 December 2020

Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators

1 reference

12 December 2020

Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference

1 reference

12 December 2020

Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society

1 reference

12 December 2020

Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial

1 reference

12 December 2020

The impact of migraine on daily activities: effect of topiramate compared with placebo

1 reference

12 December 2020

A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis

1 reference

12 December 2020

The International Classification of Headache Disorders: 2nd edition

1 reference

12 December 2020

10.1002/14651858.CD010610

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3883039

Fatcat ID

release_dd7v5axasfgdfnhlehfbbdpswi

0 references

OpenCitations bibliographic resource ID

3883039

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3883039